The Press-Pulse Protocol: Targeting Cancer's Two Fuel Sources Simultaneously

The Bottom Line

The Press-Pulse Protocol is a metabolic cancer management framework developed by Thomas Seyfried at Boston College. Unlike fasting alone, it simultaneously targets two fuel sources that cancer cells depend on: glucose and glutamine. The combination of a calorically restricted ketogenic diet (Press) with periodic fasting cycles or metabolic agents (Pulse) creates what Seyfried calls differential stress resistance, normal cells survive, cancer cells don't. The evidence is preclinical with accumulating human case reports, particularly in glioblastoma.

What It Is

The Press-Pulse Protocol is not a single treatment. It's a metabolic management strategy based on the idea that cancer is a mitochondrial metabolic disease, not primarily a genetic one. Seyfried's framework, published in Nutrition & Metabolism (2017) and expanded in a December 2024 BMC Medicine consensus paper for glioblastoma, argues that cancer cells have damaged mitochondria and depend on fermentation of glucose and glutamine to survive. Normal cells can switch to ketone bodies for energy; cancer cells cannot do so efficiently.

The Core Insight: Two Fuels, Not One

Most dietary cancer discussions focus on sugar. The Press-Pulse framework adds the second piece: glutamine. Cancer cells are glutamine-addicted. They use it for biomass building, antioxidant production, and energy. When you restrict glucose alone, cancer cells can upregulate glutamine metabolism as a compensation. Restrict both simultaneously, and you close the escape valve.

• Glucose: Cancer's primary fermentable fuel. Most tumors show elevated glucose metabolism (the Warburg effect). This is why PET scans use radioactive glucose.
• Glutamine: Cancer's second major fuel. Used for nucleotide synthesis, NADPH production, and cell signaling. Many cancers are deeply dependent on glutamine.
• Ketone bodies: Normal cells can run on ketones when glucose is low. Cancer cells with damaged mitochondria cannot. This creates differential stress resistance.

The Press Component

Press refers to chronic metabolic stress applied through a calorically restricted ketogenic diet (KD-MCT or KD-CF). The goal is to keep blood glucose low and ketone bodies elevated continuously. This creates a metabolic environment hostile to cancer growth while normal cells adapt.

• Calorie restriction: 20-30% caloric reduction from baseline. Not starvation, but sustained restriction.
• Low glucose: Minimizing dietary carbohydrates to keep insulin and IGF-1 low.
• Moderate protein: Protein restriction reduces methionine and other amino acids that cancer cells depend on.
• High fat with MCTs: Medium-chain triglycerides help raise ketone levels.
• Duration: Applied continuously as a lifestyle.

The Pulse Component

Pulse refers to acute metabolic shocks delivered periodically. When cancer cells are already metabolically stressed by the Press phase, these pulses push them toward crisis.

• Extended fasting: 3-5 day water fasts, or 7-day fasts if tolerated. The metabolic shock is stronger when cells are already stressed.
• Hyperbaric oxygen therapy (HBOT): Delivers high oxygen to tissues, counteracting the hypoxic tumor environment and supporting normal mitochondrial function.
• Glutamine-targeting agents: Compounds like 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog, or natural compounds like phenylacetate and phenylbutyrate.
• Ketone supplementation: Exogenous ketone esters can elevate ketones without food intake, potentially amplifying the Pulse.

The Seyfried Protocol: Key Papers

Press-Pulse: A Novel Therapeutic Strategy (2017)

Seyfried TN, Yu G, Maroon JC, D'Agostino DP. Published in Nutrition & Metabolism. This is the foundational paper laying out the metabolic framework, the two-fuel hypothesis, and the Press-Pulse concept. PMC5324220.

Glioblastoma Consensus Protocol (BMC Medicine, December 2024)

A multi-institutional research framework proposal for ketogenic metabolic therapy in glioblastoma. This represents the most serious clinical validation attempt to date, with a structured protocol for human trials.

Glutamine Targeting + Ketogenic Diet in Late-Stage Glioblastoma (Communications Biology, 2019)

Showed therapeutic benefit of combining calorically restricted ketogenic diet with glutamine targeting in an animal model. The combination was more effective than either approach alone.

IDH1-Mutant Glioblastoma: 80-Month Follow-Up (Frontiers in Nutrition, 2021)

An 80-month case report of long-term management of IDH1-mutant glioblastoma using ketogenic metabolic therapy without chemo or radiation. Sustained remission in a patient who declined standard treatment.

Human Clinical Evidence

Honest assessment: the bulk of evidence is preclinical. However, there are meaningful human signals.

• Glioblastoma case reports: Multiple published cases show long-term disease-free survival with metabolic therapy alone. The 80-month case is the most dramatic.
• Epilepsy literature crossover: The ketogenic diet has decades of human safety data from epilepsy treatment. This informs the safety profile even if the cancer applications differ.
• Ongoing trials: Several Phase I/II trials are recruiting or underway testing ketogenic diets in combination with standard care for glioblastoma and other cancers. Results not yet published.
• BMC Medicine 2024 consensus: The published framework for human trials represents a serious attempt to move from case reports to controlled studies.

Grade B Rationale

We grade this B (Promising) rather than C because the mechanism is exceptionally well-described in preclinical models, there are published human case reports with dramatic outcomes, the 2024 BMC Medicine consensus represents serious clinical intent, and the two-fuel model has strong mechanistic plausibility. We await controlled trial data.

Practical Considerations

Is This Do-It-Yourself?

The Press-Pulse Protocol is more complex than basic intermittent fasting. The Press phase requires significant dietary discipline and typically guidance from a metabolic or ketogenic-aware physician. The Pulse phase, particularly extended fasting, carries real risks especially for patients with cachexia, diabetes, or other metabolic conditions. This is not a protocol to start without medical supervision if you have an active cancer diagnosis.

For Prevention

The Press component (calorically restricted ketogenic diet) is more accessible as a prevention strategy. Even 14-16 hour overnight fasts show metabolic benefits. Discuss with your doctor if you have any metabolic conditions.

Drug Interactions

Many chemotherapy drugs require food intake. The Press-Pulse Protocol can interfere with standard treatment schedules. Coordination between metabolic practitioners and oncology teams is essential. Some patients work with metabolic oncologists who can time treatments around fasting cycles.

Where to Learn More

• Hippocrates Research Foundation: hippocratesresearchfoundation.org has protocols and practitioner referrals
• presspulseprotocol.com: Seyfried's group resources
• cancermitochondria.com: Research papers and educational materials

Our Assessment

The Press-Pulse Protocol is the most complete metabolic framework we've reviewed. It addresses the key limitation of fasting-only approaches by targeting glutamine alongside glucose. The mechanism is compelling, the preclinical data strong, and the 2024 clinical framework signals serious intent to move into human trials. The practical challenge is that it's difficult to execute well without medical support, and the human trial data remains limited. Worth discussing with a metabolic oncologist if you have an active diagnosis.

Sources

• PMC5324220: Press-pulse: a novel therapeutic strategy for the metabolic management of cancer (Seyfried et al., 2017)
• BMC Medicine, December 2024: Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
• Communications Biology (2019): Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma
• Frontiers in Nutrition (2021): Ketogenic metabolic therapy, without chemo or radiation, for IDH1-mutant glioblastoma (80-month case report)
• PMC4944364: Calorie restriction and ketone supplementation as a metabolic therapy for cancer (review)